3-(2-trifluoromethyl-3-aryl-4H-chromene-4-yl)-1H-indole derivative as well as preparation method and application thereof

Through structural modification and pharmacopolar splicing, the synthetic 3-(2-trifluoromethyl-3-aryl-4H-chromene-4-yl)-1H-indole derivative solves the problem of major side effects of NSAIDs. A more efficient anti-inflammatory and analgesic effect was achieved, significantly inhibiting NO release and reducing the risk of gastric ulcer, demonstrating its superiority in inflammation treatment.

CN118994121AActive Publication Date: 2024-11-22DALIAN UNIV OF TECH
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411020105.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-29
Publication Date
2024-11-22
Estimated Expiration
2044-07-29

AI Technical Summary

Technical Problem

Existing NSAIDs have significant side effects in the treatment of inflammation and pain, such as gastrointestinal reactions, renal impairment, and cardiotoxicity, and are poorly selective and cannot meet medical needs.

Method used

A 3-(2-trifluoromethyl-3-aryl-4H-chromene-4-yl)-1H-indole derivative was designed to reduce the exposure of carboxylic acid structure through structural modification, and combine with 2-tria. The activity of fluoromethylchromene and indole is synthesized by pharmacopolytic splicing method to synthesize compounds with higher anti-inflammatory activity and less side effects.

Benefits of technology

The compound exhibits better anti-inflammatory and analgesic effects in vivo than commercially available non-steroidal anti-inflammatory drugs, significantly inhibits NO release, reduces the risk of gastric ulcers, and shows significant inhibitory effects in acute and chronic inflammation models. Have good therapeutic potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994121A_ABST
    Figure CN118994121A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of medicinal chemicals, and discloses a 3-(2-trifluoromethyl-3-aryl-4H-chromene-4-yl)-1H-indole derivative, a preparation method and application, the 3-(2-trifluoromethyl-3-aryl-4H-chromene-4-yl)-1H-indole derivative has a structure as shown in a formula (I), R1 is selected from aryl groups with different substituent groups, R2 is selected from aryl groups with different substituent groups, R3 is selected from aryl groups with different substituent groups, R4 is selected from aryl groups with different substituent groups, and R4 is selected from aryl groups with different substituent groups. R2 is selected from any one or combination of-H,-F,-Cl,-CH3 and-OCH3 which are substituted at any position, and R3 is selected from any one or combination of-H,-CH3 and-OCH3 which are substituted at any position. The compounds provided by the invention can be used as anti-inflammatory drugs and analgesic drugs and are used for treating acute and chronic inflammatory reactions, tissue swelling, hyperplasia and pain, and part of the compounds show better anti-inflammatory and analgesic effects than commercially available commercial non-steroidal anti-inflammatory drugs. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of pharmaceutical chemicals, and in particular to a 3-(2-trifluoromethyl-3-aryl-4H-chromene-4-yl)-1H-indole derivative, a preparation method and application thereof. Background Art

[0002] Inflammation is one of the most important processes in the defense of organisms, however, it often develops into a disease that manifests as pain or chronic damage and requires drug treatment. In addition, inflammation is associated with various diseases, such as atherosclerosis, Alzheimer's disease, Parkinson's disease, rheumatoid arthritis and diabetes. Worldwide, the most widely used drugs for anti-inflammatory, rheumatic diseases, osteoarthritis and pain relief are mainly non-steroidal anti-inflammatory drugs (NSAIDs). About 30 million people take these drugs regularly. Due to the exposed carboxyl groups in the structure of NSAIDs and poor selectivity for COX-2 and COX-1, they have significant side effects. For example, about 107,000 people seek medical treatment for NSAID-related gastric diseases each year. In addition, they can cause renal damage, cardiac toxicity and platelet inhibition (increase the mortality rate of gastrointestinal bleeding), etc., resulting in the current NSAIDs not being able to meet medical needs. The safety of NSAIDs is highly valued worldwide, but it is undeniable that the benefits of using NSAIDs are greater than the risks (European Medicines Agency, 2006), especially in the treatment of arthritis and pain relief, which still rely on nonsteroidal anti-inflammatory drugs. Therefore, it is of great significance to develop new NSAIDs with high selectivity and fewer side effects.

[0003] Indole has attracted much attention due to its unique chemical properties and biological activities, and is often seen in many marketed drugs. Indole compounds have always played an important role in the field of anti-inflammatory drugs. Among them, indomethacin and acemetacin are potent NSAIDs that have the effect of treating various inflammatory diseases including arthritis and analgesic effects, but they are often accompanied by more serious gastrointestinal side effects, such as nausea, vomiting, abdominal pain, ulcers and even bleeding. Many researchers have reported that the reasons for indomethacin to cause gastrointestinal side effects include direct stimulation of the exposed carboxylic acid groups in its structure, disturbance of extracellular matrix (ECM) remodeling, and cell apoptosis.

[0004] CN116375738A discloses a [1,2]thiazine [3,4-b] indole compound and its preparation method and application, wherein indolin-2-imine is used as a raw material, and reacts with β-aryl vinyl sulfonyl fluoride under the action of an organic or inorganic base to obtain a target compound. However, it has not been verified what kind of anti-inflammatory effect it has in vivo, and its biological safety also needs to be studied. Summary of the invention

[0005] Chromene is a heterocyclic compound with multiple biological activities. Researchers have reported that it has anti-inflammatory, antioxidant, anticancer, antibacterial and antiviral activities. Compounds containing chromene skeletons are also widely present in natural products. Their low toxicity and wide range of pharmacological properties have inspired medicinal chemists to find new drugs. The pharmaceutical industry is also well aware of the importance of this important structure in the development of new drug candidates. Among them, many researchers have reported that 2-trifluoromethylchromene has excellent anti-inflammatory activity as a selective COX-2 inhibitor. Combined with previous research work, 2-trifluoromethylchromene is now used as a lead compound and its structure is modified. It has been reported that the exposed carboxylic acid structure in the structure of NSAIDs dissolves the phospholipids of mucosal epithelial cells, thereby increasing the permeability of the mucosa and eventually causing severe gastric ulcers. The reported structures all have a carboxylic acid structure attached to the 3-position of the chromene ring. In order to reduce the digestive tract irritation caused by the exposed carboxylic acid, the carboxyl structure is replaced, that is, the aromatic group is used to replace the carboxylic acid at the 3-position for structural modification.

[0006] ECM remodeling is attributed to the activity of various matrix metalloproteinases (MMPs), especially the increased activity of MMP-9, which often participates in the degradation of basement membrane collagen during tissue remodeling. Increased MMP-9 activity is associated with gastrointestinal inflammation caused by NSAIDs, resulting in damage to the integrity of the gastric ECM. However, some researchers have converted the ulcerogenicity of indomethacin into anti-ulcerogenicity by chemically modifying it. Moreover, MMP-9 inhibitors based on indole have been discovered for a long time, and researchers have previously reported that melatonin (a naturally occurring indole derivative) can effectively inhibit MMP-9.

[0007] Pharmacophore splicing is one of the important strategies in drug design and development. It integrates the advantages of multiple known pharmacophores, expands the chemical space of drugs, and provides a new way to discover new lead compounds. At the same time, it also helps to solve problems such as drug resistance, and brings hope for improving the performance of existing drugs and developing new treatment options. However, pharmacophore splicing also faces some challenges, such as the stability and toxicity of the spliced ​​compounds, which need to be fully evaluated and optimized. Despite this, pharmacophore splicing is still a very promising method in the field of drug research, and it continues to promote the progress of drug research and development. In summary, combining the activity of 2-trifluoromethylchromene and indole structure, using the pharmacophore splicing principle to synthesize 3-(2-trifluoromethyl-3-aryl-4H-chromene-4-yl)-1H-indole derivatives with higher activity and less side effects is the design idea of ​​the present invention.

[0008] On the basis of the above research, in order to solve the problems existing in the prior art, the present invention designs and synthesizes a 3-(2-trifluoromethyl-3-aryl-4H-chromen-4-yl)-1H-indole derivative with good anti-inflammatory activity. Specifically, the trifluoromethylimine derivative provided by the present invention has a structure shown in the following general formula (I):

[0009]

[0010] in,

[0011] R 1 Any one selected from a five-membered aromatic ring or a six-membered aromatic ring substituted with hydrogen, halogen, a C6 or lower hydrocarbon group, a C3 or lower fluoroalkyl group, or a C4 or lower alkoxy group, preferably any one of -C6H5, -2-F-C6H4, -3-F-C6H4, -4-F-C6H4, -2-Cl-C6H4, -4-Cl-C6H4, -3-Br-C6H4, -4-Br-C6H4, -4-CF3-C6H4, -2-OCH3-C6H4, -4-OCH3-C6H4, -3-CH3-C6H4, -4-CH3-C6H4, -4-Ph-C6H4, and a thienyl group;

[0012] R 2 Any one or combination selected from hydrogen, halogen, C5 or less alkyl and alkoxy substituted at any position, preferably any one or combination of -H, -5-Cl, -6-F, -6-Cl, -6-CH3, -7-CH3, -6-OCH3, -7-OCH3, R 3 Any one or a combination thereof selected from -H, -CH3, -OCH3 substituted at any position;

[0013] Preferably, the compound represented by the general formula (I) is selected from one of the following structural formulas:

[0014]

[0015] The present invention also provides a method for preparing any of the above 3-(2-trifluoromethyl-3-aryl-4H-chromen-4-yl)-1H-indole derivatives (I). The synthetic route of the compound represented by the above formula (I) is:

[0016]

[0017] In formula (I)-(V), R 1 , R 2 , R 3 is as defined above;

[0018] The specific synthesis method is:

[0019] Using a 2-aryl substituted carboxylic acid represented by formula (V) as a raw material, a ketone compound represented by formula (IV) is prepared by Friedel-Crafts acylation reaction;

[0020] Using a ketone compound represented by formula (IV) as a raw material, an ester / ketone exchange reaction is performed to generate a (Z)-trifluoromethanesulfonic acid trifluoromethyl alkenyl ester compound represented by formula (III);

[0021] The (Z)-trifluoromethanesulfonic acid trifluoromethyl alkenyl ester compound represented by formula (III) is used as a raw material, and R 2 The substituted salicylaldehyde undergoes a condensation cyclization reaction to produce a 2-trifluoromethyl-2-hydroxy-3-aryl-2H-chromene represented by formula (II);

[0022] Then, 2-trifluoromethyl-2-hydroxy-3-aryl-2H-chromene represented by formula (II) is used as a raw material and R 3 The substituted indole undergoes a nucleophilic substitution reaction to produce a 3-(2-trifluoromethyl-3-aryl-4H-chromen-4-yl)-1H-indole derivative represented by formula (I).

[0023] The present invention also provides the use of any of the above 3-(2-trifluoromethyl-3-aryl-4H-chromene-4-yl)-1H-indole derivatives (I), specifically for preparing anti-inflammatory and analgesic drugs.

[0024] Preferably, the drugs used in the test are, but not limited to, those for treating acute and chronic inflammation and pain in the examples.

[0025] The 3-(2-trifluoromethyl-3-aryl-4H-chromene-4-yl)-1H-indole derivative (I) provided by the present invention can be used as an effective ingredient in a drug for treating acute and chronic inflammation and the accompanying hyperplasia and pain.

[0026] The beneficial effects of the present invention compared with the prior art are:

[0027] The compounds provided by the invention can be used to prepare anti-inflammatory drugs and analgesics, and are used for the treatment of acute and chronic inflammatory reactions, tissue redness, swelling, hyperplasia and pain. Some compounds show better anti-inflammatory and analgesic effects than commercial non-steroidal anti-inflammatory drugs on the market. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 It is a cell viability assay for 3-(2-trifluoromethyl-3-aryl-4H-chromen-4-yl)-1H-indole derivatives (I);

[0029] Figure 2 It is the inhibitory effect of 3-(2-trifluoromethyl-3-aryl-4H-chromen-4-yl)-1H-indole derivatives (I) on NO release;

[0030] Figure 3 It is the inhibitory effect of compound I-25 on cotton ball implantation-induced granuloma in mice;

[0031] Figure 4 It is the inhibitory effect of compound I-25 on acetic acid-induced writhing in mice;

[0032] Figure 5 The therapeutic effect of compound 1-25 on adjuvant-induced arthritis in rats: Effects of compound 1-25 on (A) body weight, (B) left hind paw volume, (C) arthritis score, (D) 50% mechanical pain threshold (50% MWT) and (E) spleen weight of AIA rats. DETAILED DESCRIPTION

[0033] In order to enable those skilled in the art to better understand and implement the technical solution of the present invention, the present invention is further described below in conjunction with specific embodiments, but the embodiments are not intended to limit the present invention in any way.

[0034] The test methods described in the following examples are conventional methods unless otherwise specified; the reagents and materials described are commercially available unless otherwise specified.

[0035] The structures, physical properties and 1 H NMR, 19 FNMR, 13 C NMR and HRMS data, but the present invention is not limited to these compounds.

[0036] I-1: light yellow liquid, yield 67%. 1 H NMR(400MHz, CDCl3)δ7.95(s,1H,NH),7.40-7.36(m,1H,ArH),7.34-7.29(m,1H,ArH),7.20- 7.12(m,3H,(ArH)3),7.08-6.97(m,3H,(ArH)3),6.88-6.80(m,5H,(ArH)5),4.93(s,1H,CH). 19 F NMR(377MHz, CDCl3)δ-64.13(3F),-114.30(1F). 13C NMR (101 MHz, CDCl3) δ 162.3 (d, J = 246.6 Hz), 149.5, 136.6, 136.0 (q, J = 34.5 Hz), 131.9 (d, J = 3.5 Hz), 130.3 (q, J = 8.3 Hz), 129.1, 128.0, 125.8, 124.6, 123.0, 122.6, 122.4, 120.1, 120.0 (q, J = 275.3 Hz), 119.8, 119.0, 117.8, 116.3, 114.8 (d, J = 21.5 Hz), 111.4, 40.2. HRMS (ESI) m / z: calculated value C 24 H 14 F4NO[MH] - 408.1017, measured value: 408.1025.

[0037] I-2: light yellow liquid, yield 62%. 1 H NMR(400MHz, CDCl3)δ7.96(s,1H,NH),7.42-7.37(m,1H,ArH),7.33-7.26(m,3H,(ArH)3),7.22-7.15(m ,3H,(ArH)3),7.10-6.98(m,3H,(ArH)3),6.87(s,1H,ArH),6.78-6.72(m,2H,(ArH)2),4.94(s,1H,CH). 19 F NMR (377MHz,CDCl3)δ-64.13. 13 C NMR (101 MHz, CDCl3) δ 149.4, 136.7, 136.0 (q, J = 34.5 Hz), 135.0, 131.0, 130.3, 129.1, 128.0, 125.7, 124.7, 122.8, 122.6, 122.4, 121.9, 120.1, 120.0 (q, J = 275.3 Hz), 119.6, 119.0, 117.6, 116.3, 111.4, 40.0. HRMS (ESI) m / z: calculated value C 24 H 14 BrF3NO[MH] - 468.0216, measured value: 468.0212.

[0038] I-3: light yellow liquid, yield 71%. 1H NMR(400MHz, CDCl3)δ7.98(s,1H,NH),7.44-7.33(m,4H,(ArH)4),7.22-7.14(m, 3H,(ArH)3),7.11-6.97(m,5H,(ArH)5),6.89-6.83(m,1H,ArH),4.97(s,1H,CH). 19 F NMR(377MHz, CDCl3)δ-62.62(3F),-64.25(3F). 13 C NMR (101 MHz, CDCl3) δ 149.4, 139.8, 136.7, 136.2 (q, J = 34.9 Hz), 129.9 (q, J = 32.4 Hz), 129.2, 129.0, 128.1, 125.7, 124.81 (q, J = 4.0 Hz), 124.76, 122.8 (q, J = 286.8 Hz), 122.7, 122.6, 122.5, 120.1, 120.0 (q, J = 275.3 Hz), 119.5 (q, J = 2.0 Hz), 118.9, 117.4, 116.4, 111.5, 40.0. HRMS (ESI) m / z: calculated value C 25 H 14 F6NO[MH] - 458.0985, measured value: 458.0986.

[0039] I-4: colorless liquid, yield 52%. 1 H NMR(400MHz, CDCl3)δ7.96(s,1H,NH),7.21-7.05(m,5H,(ArH)5),6.99-6.91(m,4H,(Ar H)4),6.71-6.63(m,1H,ArH),6.62-6.53(m,1H,ArH),5.03(s,1H,CH),2.44(s,3H,CH3). 19 F NMR(377MHz, CDCl3)δ-64.28(3F),-113.17(1F). 13C NMR (101 MHz, CDCl3) δ 162.2 (d, J = 246.2 Hz), 151.1, 137.6 (d, J = 8.1 Hz), 136.0, 135.7 (q, J = 35.1 Hz), 134.0, 129.5 (d, J = 8.4 Hz), 128.6, 125.8, 125.3, 124.7, 124.2, 122.8, 121.6, 120.6, 120.4, 120.0 (q, J = 275.3 Hz), 116.7, 115.7, 115.2, 115.0 (d, J = 21.0 Hz), 38.8, 16.5. HRMS (ESI) m / z: calculated value C 25 H 15 ClF4NO[MH] - 456.0784, measured value: 456.0783.

[0040] I-5: light yellow liquid, yield 59%. 1 H NMR(400MHz, CDCl3)δ7.98(s,1H,NH),7.20-7.07(m,5H,(ArH)5),6.98-6.78(m,4H,(ArH) )4),6.70-6.62(m,1H,ArH),6.61-6.54(m,1H,ArH),5.00(s,1H,CH),3.74(s,3H,OCH3). 19 F NMR(377MHz, CDCl3)δ-64.44(3F),-113.24(1F). 13 C NMR (101 MHz, CDCl3) δ 162.2 (d, J = 246.5 Hz), 154.3, 151.0, 137.5 (d, J = 8.3 Hz), 135.6 (q, J = 35.2 Hz), 134.0, 131.4, 129.5 (d, J = 8.4 Hz), 128.6, 125.9, 124.9, 124.6, 121.3, 120.5, 120.0 (q, J = 275.3 Hz), 115.0 (d, J = 21.2 Hz), 114.9, 112.8, 112.3, 102.4 (d, J = 4.3 Hz), 99.9, 55.4, 38.6. HRMS (ESI) m / z: calculated value C 25 H 15 ClF4NO2[MH] - 472.0733, measured value: 472.0735. I-6: light yellow liquid, yield 66%. 1H NMR(400MHz, CDCl3)δ8.05(s,1H,NH),7.41-7.31(m,3H,(ArH)3),7.20-7.13(m,3H,(ArH)3) ,7.09-7.01(m,4H,(ArH)4),6.96-6.91(m,1H,ArH),6.76-6.67(m,1H,ArH),5.02(s,1H,CH). 19 F NMR (377MHz,CDCl3)δ-64.38. 13 C NMR (101 MHz, CDCl3) δ 151.0, 137.5, 136.4, 135.7 (q, J = 35.2 Hz), 134.0, 131.3, 131.1, 129.4, 128.6, 127.6, 125.8, 125.7, 124.4, 122.2, 121.8, 121.4, 120.5 (q, J = 2.3 Hz), 120.1, 120.0 (q, J = 275.3 Hz), 118.6, 115.13, 115.06, 111.5, 38.6. HRMS (ESI) m / z: calculated value C 24 H 13 BrClF3NO[MH] - 501.9827, measured value: 501.9829.

[0041] I-7: colorless liquid, yield 52%. 1 H NMR(400MHz, CDCl3)δ7.92(s,1H,NH),7.44-7.40(m,1H,ArH),7.24-7.04(m,5H,(ArH)5) ,6.87-6.75(m,4H,(ArH)4),6.36-6.30(m,1H,ArH),5.10(s,1H,CH),3.72(s,3H,OCH3). 19 F NMR (377MHz,CDCl3)δ-65.85. 13 C NMR (101 MHz, CDCl3) δ 154.2, 151.1, 136.0 (q, J = 35.1 Hz), 134.2, 133.5, 132.2, 132.1, 131.3, 129.4, 129.1, 128.5, 126.3, 125.93, 125.90, 124.9, 121.1, 120.0 (q, J = 275.3 Hz), 119.4 (q, J = 2.4 Hz), 114.9, 114.8, 112.7, 112.2, 99.9, 55.4, 36.8. HRMS (ESI) m / z: calculated value C 25 H15 Cl2F3NO2[MH] - 488.0437, measured value: 488.0439.

[0042] I-8: light yellow liquid, yield 70%. 1 H NMR(400MHz, CDCl3)δ8.00(s,1H,NH),7.42-7.36(m,1H,ArH),7.35-7.31(m,1H,ArH),7.17-7.12(m,3H,(ArH)3),7.08-7.02(m, 2H,(ArH)2),6.97-6.93(m,1H,ArH),6.83-6.77(m,2H,(ArH)2),6.73-6.68(m,2H,(ArH)2),5.04(s,1H,CH),3.75(s,3H,OCH3). 19 F NMR (377 MHz, CDCl3) δ-64.20. 13 C NMR (101 MHz, CDCl3) δ 159.2, 151.2, 136.3, 135.5 (q, J = 35.1 Hz), 133.9, 129.8, 128.3, 127.7, 125.8, 125.5, 124.3, 122.0, 121.94, 121.90, 120.0 (q, J = 275.3 Hz), 119.98, 119.1, 115.7, 115.1, 113.3, 111.3, 55.2, 38.9. HRMS (ESI) m / z: calculated value C 25 H 16 ClF3NO2[MH] - 454.0827, measured value: 454.0824.

[0043] I-9: light yellow liquid, yield 56%. 1 H NMR(400MHz, CDCl3)δ8.07(s,1H,NH),7.41-7.36(m,1H,ArH),7.29-7.22(m,1H ,ArH),7.16-6.99(m,3H,(ArH)3),6.85-6.70(m,7H,(ArH)7),4.88(s,1H,CH). 19 F NMR(377MHz, CDCl3)δ-63.90(3F),-113.89(1F),-118.01(1F). 13C NMR(101MHz, CDCl3)δ162.4(d,J=246.9Hz),159.3(d,J=242.8Hz),145.6,136.7,1 36.1(q,J=34.4Hz),131.6(d,J=3.5Hz),130.4,130.3,125.6,124.4(d,J=7.5Hz),1 22.6 (d, J = 19.7 Hz), 120.2, 120.0 (q, J = 275.3 Hz), 118.9, 117.74, 117.66, 117.1, 115.3 (d, J = 6.8 Hz), 115.08, 115.05, 115.0, 114.8, 111.6, 40.5. HRMS (ESI) m / z: calculated value C 24 H 13 F5NO[MH] - 426.0923, measured value: 426.0927.

[0044] I-10: light yellow liquid, yield 65%. 1 H NMR(400MHz, CDCl3)δ7.89(s,1H,NH),7.25-7.21(m,1H,ArH),7.12-7.07(m,1H,ArH),6 .99-6.96(m,2H,(ArH)2),6.87-6.81(m,7H,(ArH)7),4.89(s,1H,CH),2.43(s,3H,CH3). 19 F NMR(377MHz, CDCl3)δ-63.97(3F),-113.97(1F),-118.11(1F). 13 C NMR (101MHz, CDCl3) δ162.4 (d, J = 246.8Hz), 159.3 (d, J = 242.7Hz), 145.6, 136.3, 136.0 (q, J=35.1Hz),131.6(d,J=3.5Hz),130.4(d,J=8.1Hz),125.2,124.5(d,J=7.5Hz),123.1,122 .4,120.7,120.4,120.0 (q, J = 275.3 Hz),118.9,117.7,117.64,117.55,116.6,115.2 (d, J = 3.7 Hz),115.01 (d, J = 3.7 Hz),114.95 (d, J = 21.2 Hz),114.8,40.6,16.5. HRMS (ESI) m / z: calculated value C 25 H 15 F5NO[MH] -440.1079, measured value: 440.1076.

[0045] I-11: light yellow liquid, yield 53%. 1 H NMR(400MHz, CDCl3)δ7.98(s,1H,NH),7.42-7.34(m,1H,ArH),7.33-7.27(m,2H,(ArH)2),7.17-7.10(m,3H,(ArH)3) ,7.04-6.98(m,1H,ArH),6.92-6.87(m,1H,ArH),6.82-6.73(m,3H,(ArH)3),6.41-6.32(m,1H,ArH),5.10(s,1H,CH). 19 F NMR(377MHz, CDCl3)δ-65.75(3F),-118.19(1F). 13 C NMR (101 MHz, CDCl3) δ 159.3 (d, J = 242.7 Hz), 145.6, 136.7, 136.5 (q, J = 35.2 Hz), 133.7, 132.3, 132.0, 129.2 (d, J = 22.2 Hz), 125.9, 125.8, 124.1 (d, J = 7.5 Hz), 122.9, 122.4, 120.1, 120.0 (q, J = 275.3 Hz), 118.9, 117.7 (d, J = 8.4 Hz), 117.4, 116.9, 115.6, 115.4, 115.1, 111.5, 38.1. HRMS (ESI) m / z: calculated value C 24 H 13 ClF4NO[MH] - 442.0627, measured value: 442.0630.

[0046] I-12: light yellow liquid, yield 95%. 1 H NMR (400MHz, CDCl3) δ7.88(s,1H,NH),7.36-7.30(m,1H,ArH),7.28-7.24(m,1H,ArH),7.19-6.99(m,4H,(ArH)4),6.91-6.82( m,2H,(ArH)2),6.78-6.72(m,2H,(ArH)2),6.55-6.48(m,1H,ArH),6.40-6.32(m,1H,ArH),5.07(s,1H,CH),3.83(s,3H,OCH3). 19 F NMR(377MHz, CDCl3)δ-65.28(3F),-118.81(1F).13 C NMR (101 MHz, CDCl3) δ 159.2 (d, J = 242.1 Hz), 156.1, 145.9, 136.6, 135.8 (q, J = 34.3 Hz), 131.6, 129.2, 125.9, 124.7 (d, J = 7.4 Hz), 123.8, 122.7, 122.2, 120.0 (q, J = 275.3 Hz), 119.8 (d, J = 11.9 Hz), 119.0, 117.6, 117.5, 115.5, 115.3, 115.0, 114.8, 111.4, 110.4, 55.6, 38.1. HRMS (ESI) m / z: calculated value C 25 H 16 F4NO2[MH] - 438.1123, measured value: 438.1121.

[0047] I-13: light yellow liquid, yield 80%. 1 H NMR (400MHz, CDCl3) δ7.86(s,1H,NH),7.41-7.35(m,1H,ArH),7.31-7.24(m,1H,ArH),7.22-6.94(m ,5H,(ArH)5),6.92-6.71(m,4H,(ArH)4),6.67-6.58(m,1H,ArH),4.91(s,1H,CH),2.18(s,3H,CH3). 19 F NMR(377MHz, CDCl3)δ-64.00(3F),-118.30(1F). 13 C NMR (101 MHz, CDCl3) δ 159.2 (d, J = 242.7 Hz), 145.9, 137.5, 136.7, 135.74 (q, J = 34.5 Hz), 135.69, 129.1, 128.6, 127.8, 125.79, 125.76, 124.9 (d, J = 7.5 Hz), 122.7, 122.4, 120.3, 120.1, 120.0 (q, J = 275.3 Hz), 119.0, 117.7, 117.6, 117.3, 115.1, 111.5 (d, J = 24.2 Hz), 40.6, 21.3. HRMS (ESI) m / z: calculated value C 25 H 16 F4NO[MH] - 422.1174, measured value: 422.1170.

[0048] I-14: colorless liquid, yield 55%. 1H NMR(400MHz,CDCl3)δ7.89(s,1H,NH),7.28-7.23(m,1H,ArH),7.13-7.07(m,1H,ArH),7.03-6.99(m,2H,(ArH)2),6.98-6.95(m,2H,(ArH) )2),6.87-6.83(m,2H,(ArH)2),6.78-6.75(m,2H,(ArH)2),6.67-6.59(m,1H,ArH),4.90(s,1H,CH),2.42(s,3H,CH3),2.20(s,3H,CH3). 19 FNMR(377MHz, CDCl3)δ-64.13(3F),-118.47(1F). 13 C NMR (101 MHz, CDCl3) δ 159.2 (d, J = 242.5 Hz), 145.8, 137.5, 136.3, 135.75 (q, J = 34.8 Hz), 135.69, 129.0, 128.6, 127.7, 125.8, 125.3, 123.5, 122.9, 122.3, 120.5, 120.2, 120.0 (q, J = 275.3 Hz), 118.7, 117.9, 117.6 (d, J = 8.3 Hz), 116.7, 114.9 (d, J = 25.2 Hz), 111.7, 40.6, 21.3, 16.5. HRMS (ESI) m / z: calculated value C 26 H 18 F4NO[MH] - 436.1330, Found: 436.1331.I-15: Pale yellow liquid, yield 78%. 1 H NMR(400MHz,CDCl3)δ7.94(s,1H,NH),7.43-7.37(m,1H,ArH),7.35-7.29(m,1H,ArH),7.19-7.13(m,1H,ArH),7.13-7.08(m,1H,ArH),7.0 7-7.02(m,1H,ArH),6.97-6.92(m,2H,(ArH)2),6.90-6.85(m,2H,(ArH)2),6.80-6.72(m,3H,(ArH)3),4.91(s,1H,CH),2.26(s,3H,CH3). 19 F NMR(377MHz, CDCl3)δ-63.94(3F),-118.38(1F). 13C NMR (101 MHz, CDCl3) δ 159.2 (d, J = 242.5 Hz), 145.8, 135.8 (q, J = 34.5 Hz), 136.7, 135.6, 132.8, 128.9, 128.6, 128.4, 125.7, 124.8, 122.7, 122.4, 120.1, 120.0 (q, J = 275.3 Hz), 119.0, 117.7, 117.6, 117.4, 115.0 (d, J = 23.2 Hz), 111.5, 40.6, 21.2. HRMS (ESI) m / z: calculated value C 25 H 16 F4NO[MH] - 422.1174, measured value: 422.1172.

[0049] I-16: light yellow liquid, yield 58%. 1 H NMR(400MHz, CDCl3)δ7.84(s,1H,NH),7.30-7.25(m,1H,ArH),7.12-7.05(m,1H,ArH),7.00-6.92 (m,4H,(ArH)4),6.87-6.73(m,5H,(ArH)5),4.89(s,1H,CH),2.41(s,3H,CH3),2.25(s,3H,CH3). 19 FNMR(377MHz, CDCl3)δ-64.00(3F),-118.45(1F). 13 C NMR (101 MHz, CDCl3) δ 159.2 (d, J = 242.6 Hz), 145.7, 137.5, 136.3, 135.8 (q, J = 34.5 Hz), 132.8, 128.6, 128.4, 125.2, 124.9 (d, J = 7.5 Hz), 123.0, 122.3, 120.5, 120.29 (q, J = 275.3 Hz), 120.26, 120.0 (q, J = 2.4 Hz), 117.9, 117.6, 117.5, 116.7, 114.9 (d, J = 22.2 Hz), 40.6, 21.2, 16.5. HRMS (ESI) m / z: calculated value C 26 H 18 F4NO[MH] - 436.1330, measured value: 436.1228.

[0050] I-17: light yellow liquid, yield 56%. 1H NMR (400MHz, CDCl3) δ7.96(s,1H,NH),7.42-7.38(m,1H,ArH),7.34-7.29(m,1H,ArH),7.19-7.03(m,3H,(ArH)3),6. 90-6.85(m,2H,(ArH)2),6.81-6.74(m,3H,(ArH)3),6.70-6.66(m,2H,(ArH)2),4.90(s,1H,CH),3.72(s,3H,OCH3). 19 FNMR(377MHz, CDCl3)δ-64.03(3F),-118.51(1F). 13 C NMR (101 MHz, CDCl3) δ 159.2 (d, J = 242.6 Hz), 159.1, 145.7, 136.7, 135.9 (q, J = 34.2 Hz), 129.7, 127.9, 125.7, 124.8 (d, J = 7.5 Hz), 122.7, 122.4, 120.3 (q, J = 275.3 Hz), 120.1, 119.7 (q, J = 2.3 Hz), 119.0, 117.7, 117.6, 117.4, 115.0 (d, J = 23.2 Hz), 113.3, 111.5, 55.1, 40.6. HRMS (ESI) m / z: calculated value C 25 H 16 F4NO2[MH] - 438.1123, measured value: 438.1120.

[0051] I-18: light yellow liquid, yield 50%. 1 H NMR(400MHz, CDCl3)δ8.00(s,1H,NH),7.39-7.31(m,1H,ArH),7.23-7.18(m,1H,ArH),7.17-7.04(m,2H,(ArH)2),7.03-6.95( m,1H,ArH),6.93-6.86(m,1H,ArH),6.86-6.79(m,2H,(ArH)2),6.79-6.70(m,3H,(ArH)3),4.85(s,1H,CH),3.74(s,3H,OCH3). 19 F NMR(377MHz, CDCl3)δ-64.31(3F),-117.92(1F). 13C NMR (101 MHz, CDCl3) δ 159.3 (d, J = 243.0 Hz), 154.2, 145.6, 137.7, 136.0 (q, J = 34.8 Hz), 131.7, 131.3, 131.0, 129.4, 127.6, 125.9, 124.2 (d, J = 7.4 Hz), 123.3, 121.8, 120.0 (q, J = 274.5 Hz), 118.3, 117.5 (d, J = 8.4 Hz), 116.5, 115.3 (d, J = 24.2 Hz), 112.7 (d, J = 60.6 Hz), 100.0, 55.5, 40.4. HRMS (ESI) m / z: calculated value C 25 H 15 BrF4NO2[MH] - 516.0226, Found: 516.0228. I-19: Pale yellow liquid, yield 50%. 1 H NMR (400MHz, CDCl3) δ8.08(s,1H,NH),7.48-7.43(m,1H,ArH),7.36-7.31(m,1H,ArH),7.21-7.16(m,2H, (ArH)2),7.13-6.99(m,3H,(ArH)3),6.92-6.78(m,3H,(ArH)3),6.70-6.67(m,1H,ArH),4.96(s,1H,CH). 19 F NMR(377MHz, CDCl3)δ-63.84(3F),-117.74(1F). 13 C NMR (101 MHz, CDCl3) δ 159.4 (d, J = 243.0 Hz), 145.2, 137.3 (q, J = 34.6 Hz), 136.7, 135.7, 128.2, 126.4 (d, J = 20.2 Hz), 125.8, 124.6 (d, J = 7.6 Hz), 123.2, 122.5, 120.3 (q, J = 274.5 Hz), 120.2, 118.8, 117.9, 117.8, 117.6, 115.3 (d, J = 12.4 Hz), 114.9 (d, J = 12.0 Hz), 113.4, 111.6, 40.5. HRMS (ESI) m / z: calculated value C 22 H 12 F4NOS[MH] - 414.0581, measured value: 414.0579.

[0052] I-20: colorless liquid, yield 77%. 1H NMR(400MHz, CDCl3)δ7.95(s,1H,NH),7.41-7.35(m,1H,ArH),7.33-7.27(m,1H ,ArH),7.26-7.08(m,8H,(ArH)8),7.00-6.82(m,3H,(ArH)3),4.91(s,1H,CH). 19 F NMR (377MHz,CDCl3)δ-64.13. 13 C NMR (101 MHz, CDCl3) δ 148.2, 136.7, 135.7 (q, J = 34.7 Hz), 135.6, 129.3, 128.9, 128.5, 128.2, 127.93, 127.89, 125.7, 124.8, 122.8, 122.5, 120.7 (q, J = 2.3 Hz), 120.2 (q, J = 274.5 Hz), 120.1, 119.0, 117.8, 117.2, 111.5, 40.2. HRMS (ESI) m / z: calculated value C 24 H 14 ClF3NO[MH] - 424.0721, measured value: 424.0724.

[0053] I-21: light yellow liquid, yield 53%. 1 H NMR (400MHz, CDCl3) δ7.79(s,1H,NH),7.53-7.46(m,2H,(ArH)2),7.45-7.41(m,1H,ArH),7.40-7.33(m,4H,(ArH)4),7.29-7.22( m,2H,(ArH)2),7.14-7.09(m,1H,ArH),7.04-6.92(m,5H,(ArH)5),6.80-6.75(m,2H,(ArH)2),4.93(s,1H,CH),2.27(s,3H,CH3). 19 F NMR (377MHz,CDCl3)δ-63.85. 13C NMR (101 MHz, CDCl3) δ 149.5, 140.6, 140.3, 138.1, 136.7, 135.9 (q, J = 34.2 Hz), 135.3, 129.0, 128.8, 127.4, 127.0, 126.5, 126.2, 125.9, 125.5, 122.6, 122.3, 120.8, 120.4 (q, J = 274.5 Hz), 120.3, 119.9, 119.2, 118.2, 116.6, 111.4, 40.0, 21.1. HRMS (ESI) m / z: calculated value C 31 H 21 F3NO[MH] - 480.1581, measured value: 480.1580.

[0054] I-22: light yellow liquid, yield 54%. 1 H NMR(400MHz, CDCl3)δ7.93(s,1H,NH),7.40-7.35(m,1H,ArH),7.33-7.29(m,1H,ArH),7.17-7.08(m,2H,(ArH)2 ),7.04-6.78(m,6H,(ArH)6),6.70-6.62(m,1H,ArH),6.62-6.54(m,1H,ArH),4.91(s,1H,CH),2.30(s,3H,CH3). 19 F NMR(377MHz, CDCl3)δ-64.31(3F),-113.60(1F). 13 C NMR (101 MHz, CDCl3) δ 162.1 (d, J = 246.0 Hz), 149.3, 138.3, 138.2, 136.7, 136.1 (q, J = 34.8 Hz), 129.3 (d, J = 8.4 Hz), 128.8, 125.8, 125.6, 124.5, 122.4, 122.3, 120.1 (q, J = 274.5 Hz), 120.0, 119.9, 119.6, 119.0, 117.9, 116.6, 115.7 (d, J = 22.1 Hz), 114.6 (d, J = 21.0 Hz), 111.3, 39.8, 21.0. HRMS (ESI) m / z: calculated value C 25 H 16 F4NO[MH] - 422.1174, measured value:422.1174.

[0055] I-23: light yellow liquid, yield 81%. 1H NMR (400MHz, CDCl3) δ7.89(s,1H,NH),7.40-7.35(m,1H,ArH),7.31-7.27(m,1H,ArH),7.17-7.08(m,3 H,(ArH)3),7.04-6.92(m,3H,(ArH)3),6.84-6.76(m,4H,(ArH)4),4.88(s,1H,CH),2.29(s,3H,CH3). 19 F NMR (377 MHz, CDCl3) δ-64.00. 13 C NMR (101 MHz, CDCl3) δ 149.2, 138.2, 136.7, 136.0 (q, J = 34.4 Hz), 134.6, 133.6, 130.0, 128.8, 128.1, 125.7, 125.6, 122.5, 122.3, 120.2 (q, J = 274.5 Hz), 120.0, 119.8, 119.6 (q, J = 2.7 Hz), 119.1, 117.8, 116.6, 111.4, 39.9, 21.0. HRMS (ESI) m / z: calculated value C 25 H 16 ClF3NO[MH] - 438.0878, measured value: 438.0883.

[0056] I-24: light yellow liquid, yield 70%. 1 H NMR(400MHz, CDCl3)δ7.89(s,1H,NH),7.46-7.38(m,1H,ArH),7.30-7.25(m,1H,ArH),7.16-7.10(m,1H,ArH),7.05-7.00(m,1H,ArH) ,7.00-6.88(m,4H,(ArH)4),6.86-6.81(m,1H,ArH),6.81-6.72(m,3H,(ArH)3),4.90(s,1H,CH),2.29(s,3H,CH3),2.26(s,3H,CH3). 19 F NMR (377MHz,CDCl3)δ-64.05. 13C NMR (101 MHz, CDCl3) δ 149.5, 138.0, 137.4, 136.7, 135.8 (q, J = 34.1 Hz), 133.3, 128.8, 128.6, 128.5, 125.9, 125.5, 122.5, 122.2, 121.2, 120.5, 120.4 (q, J = 274.5 Hz), 119.9, 119.2, 118.2, 116.6, 111.4, 40.1, 21.2, 21.1. HRMS (ESI) m / z: calculated value C 26 H 19 F3NO[MH] - 418.1424, measured value: 418.1426.

[0057] I-25: light yellow liquid, yield 58%. 1 H NMR(400MHz, CDCl3)δ7.95(s,1H,NH),7.41-7.37(m,1H,ArH),7.34-7.29(m,1H,ArH),7.19-7.02(m,5H,(ArH)5) ,6.87-6.83(m,1H,ArH),6.81-6.73(m,3H,(ArH)3),6.57-6.53(m,1H,ArH),4.88(s,1H,CH),3.64(s,3H,OCH3). 19 FNMR (377MHz,CDCl3)δ-64.07. 13 C NMR (101 MHz, CDCl3) δ 156.3, 143.6, 136.7, 136.2 (q, J = 34.5 Hz), 134.6, 133.6, 130.0, 128.1, 125.7, 123.6, 122.6, 122.4, 120.4 (q, J = 274.5 Hz), 120.0, 119.0, 118.5 (q, J = 2.6 Hz), 117.4, 117.2, 114.1, 113.2, 111.4, 55.5, 40.5. HRMS (ESI) m / z: calculated value C 25 H 16 ClF3NO2[MH] - 454.0827, measured value: 454.0825.

[0058] I-26: light yellow liquid, yield 51%. 1H NMR(400MHz, CDCl3)δ7.91(s,1H,NH),7.19-7.07(m,4H,(ArH)4),6.83-6.73(m,6H,(A rH)6),6.60-6.53(m,1H,ArH),4.82(s,1H,CH),3.73(s,3H,OCH3),3.64(s,3H,OCH3). 19 F NMR (377MHz,CDCl3)δ-64.12. 13 C NMR (101 MHz, CDCl3) δ 156.4, 154.1, 143.7, 136.0 (q, J = 34.6 Hz), 134.6, 133.7, 131.7, 130.1, 128.1, 126.1, 123.4, 123.1, 120.2 (q, J = 274.5 Hz), 118.4 (q, J = 2.2 Hz), 117.1, 117.0, 114.2, 113.2, 112.9, 112.2, 100.2, 55.5, 55.4, 40.7. HRMS (ESI) m / z: calculated value C 26 H 18 ClF3NO3[MH] - 484.0933, Found: 484.0932. I-27: Pale yellow liquid, yield 53%. 1 H NMR(400MHz, CDCl3)δ7.95(s,1H,NH),7.46-7.40(m,1H,ArH),7.34-7.28(m,1H ,ArH),7.18-7.12(m,1H,ArH),7.10-7.00(m,2H,(ArH)2),6.89-6.85(m,1H,ArH ),6.89-6.85(m,2H,(ArH)2),6.75-6.71(m,1H,ArH),6.69-6.65(m,2H,(ArH)2) ,6.59-6.55(m,1H,ArH),4.89(s,1H,CH),3.73(s,3H,OCH3),3.64(s,3H,OCH3). 19 F NMR (377MHz,CDCl3)δ-63.93. 13C NMR (101 MHz, CDCl3) δ 159.0, 156.2, 143.8, 136.7, 136.0 (q, J = 34.6 Hz), 129.8, 128.4, 125.9, 124.1, 122.5, 122.2, 120.1 (q, J = 274.5 Hz), 119.9, 119.7, 119.2, 118.0, 117.1, 113.9, 113.2, 113.1, 111.3, 55.5, 55.1, 40.8. HRMS (ESI) m / z: calculated value C 26 H 19 F3NO3[MH] - 450.1323, measured value: 450.1322.

[0059] I-28: light yellow liquid, yield 83%. 1 H NMR (400MHz, CDCl3) δ7.92(s,1H,NH),7.39-7.30(m,2H,(ArH)2),7.17-7.07(m,2H,(ArH)2),7.05-6.99(m,1H,ArH),6.97-6.88( m,2H,(ArH)2),6.85-6.81(m,1H,ArH),6.71-6.63(m,2H,(ArH)2),6.60-6.54(m,2H,(ArH)2),4.90(s,1H,CH),3.78(s,3H,OCH3). 19 F NMR(377MHz, CDCl3)δ-64.00(3F),-118.30(1F). 13 C NMR (101 MHz, CDCl3) δ 159.2 (d, J = 242.7 Hz), 145.9, 137.5, 136.7, 135.74 (q, J = 34.7 Hz), 135.69, 129.1, 128.6, 127.8, 125.79, 125.76, 124.9 (d, J = 7.5 Hz), 122.7, 122.4, 120.3, 120.2 (q, J = 274.5 Hz), 120.1, 119.0, 117.7, 117.6, 117.3, 115.1 (d, J = 24.2 Hz), 111.5, 40.6, 21.3. HRMS (ESI) m / z: calculated value C 25 H 16 F4NO2[MH] - 438.1123, measured value: 438.1120.

[0060] I-29: light yellow liquid, yield 75%. 1H NMR (400MHz, CDCl3) δ7.92(s,1H,NH),7.37-7.30(m,2H,(ArH)2),7.18-7.09(m,3H,(ArH)3),7.04-6.99(m,1H,ArH),6.97-6. 91(m,1H,ArH),6.83-6.75(m,3H,(ArH)3),6.70-6.67(m,1H,ArH),6.58-6.53(m,1H,ArH),4.87(s,1H,CH),3.78(s,3H,OCH3). 19 F NMR (377MHz,CDCl3)δ-64.09. 13 C NMR (101 MHz, CDCl3) δ 158.3, 148.9, 135.6, 134.8 (q, J = 34.9 Hz), 133.5, 132.6, 128.9, 128.7, 127.0, 124.7, 121.5, 121.3, 119.1 (q, J = 274.5 Hz), 118.9, 118.8 (q, J = 2.3 Hz), 118.0, 116.7, 113.7, 110.9, 110.3, 99.7, 54.5, 38.6. HRMS (ESI) m / z: calculated value C 25 H 16 ClF3NO2[MH] - 454.0827, Measured value:454.0827.

[0061] All of the above target compounds can be obtained in medium to high yields, meeting the needs of new drug development.

[0062] Example 1

[0063]

[0064] First, under ice-water bath conditions, different 4-fluorophenylacetic acids (V-1, 1.0 eq, 0.050 mol), anisole (1.0 eq, 0.05 mol) and phosphoric acid (1.1 eq, 0.055 mol) were added to a round-bottom eggplant-shaped bottle. When the temperature was fully cooled to 0°C under magnetic stirring, trifluoroacetic anhydride (4.0 eq, 0.200 mol) was slowly added dropwise. After the addition was completed, the reaction solution was poured into an excess of pre-cooled sodium hydroxide solution and magnetically stirred. A white solid was precipitated within a few minutes. After suction filtration, water washing and drying, the intermediate 2-(4-fluorophenyl)-1-(4-methoxyphenyl)ethan-1-one (IV-1) was obtained.

[0065] Under argon, sodium hydride (2.0eq, 12mmol), ethyl trifluoroacetate (4.0eq, 24mmol), intermediate 2-(4-fluorophenyl)-1-(4-methoxyphenyl)ethan-1-one (compound VI-1, 1.0eq, 6mmol) were added to a Schlenk bottle, and solvent tetrahydrofuran (25mL) was added, and then the reaction system was heated to reflux and the reaction was continued for 12h. Subsequently, the reaction bottle was placed in an ice-water bath under argon protection, and after the reaction system liquid was completely cooled, trifluoromethanesulfonic anhydride (2.0eq, 12mmol) was slowly added dropwise to the system and reacted for 10min. Subsequently, water was added to quench the reaction, and the reaction solution was extracted with ethyl acetate, the organic layer was collected, and the solvent was concentrated in vacuo, and the pure intermediate (E)-3,3,3-trifluoro-1-(4-fluorophenyl)prop-1-ene-2-yl-trifluoromethanesulfonate (III-1) was obtained by separation and purification by silica gel column.

[0066] Subsequently, under argon atmosphere, (E)-3,3,3-trifluoro-1-(4-fluorophenyl)prop-1-en-2-yl-trifluoromethanesulfonate (intermediate III-1, 2.0eq, 6.0mmol), salicylaldehyde (1.0eq, 3.0mmol), tetrahydropyrrole (2.0eq, 6.0mmol) and solvent ethanol (6mL) were added to the Schlenk bottle, heated to 65°C under magnetic stirring conditions and reacted for 8h. After the reaction was completed as monitored by TLC, the solvent was removed by extraction with ethyl acetate and concentration under reduced pressure, and then separated and purified by silica gel column chromatography to obtain the intermediate 2-trifluoromethyl-2-hydroxy-3-(4-fluorophenyl)-2H-chromene (II-1).

[0067] Finally, 2-trifluoromethyl-2-hydroxy-3-(4-fluorophenyl)-2H-chromene (II-1, 1.0 eq, 1.0 mmol), indole (1.2 eq, 1.2 mmol), p-toluenesulfonic acid (0.5 eq, 0.5 mmol) and solvent acetonitrile (5 mL) were sequentially added to the reaction bottle, heated to 40°C and stirred for 12 hours. After the reaction was completed, the mixture was extracted with ethyl acetate, concentrated, and separated by silica gel column chromatography to obtain the target compound I-1.

[0068] The preparation of target compounds I-2 to I-29 refers to the target compound I-1, and the raw materials with corresponding different substituents can be changed.

[0069] Example 2

[0070] Cytotoxicity Assay of 3-(2-Trifluoromethyl-3-aryl-4H-chromen-4-yl)-1H-indole Derivatives (I)

[0071] The cell viability was determined by 3-(4,5-dimethylthiazole-2)-2,5-diphenyltetrazolium bromide cell viability assay (MTT method). The test concentration of compound (I) and positive drug indomethacin was 30 μM. RAW 264.7 cells were selected for the assay. 1×10 cells were seeded in each well of a 96-well plate. 5 cells, and the culture conditions were DMEM complete medium with 10% fetal bovine serum and 1% penicillin and streptomycin, and placed in a 37°C constant temperature incubator containing 5% CO2. 24 hours after inoculation, compound (I) or positive drug (both dissolved in DMSO, final concentration of 0.5%) was added, and lipopolysaccharide (LPS) was added 1 hour later to make its final concentration of 1μg / mL. After 24 hours of culture, MTT was added to the culture medium to a final concentration of 0.5mg / mL and continued to culture for 4 hours, then the culture medium was removed, 150μLDMSO was added to each well, the plate was vibrated for 10 minutes, and the absorbance at a wavelength of 570nm was measured with an enzyme reader. The test results are as follows Figure 1 All compounds showed no cytotoxicity at the tested concentrations.

[0072] Example 3

[0073] Determination of the inhibitory effect of 3-(2-trifluoromethyl-3-aryl-4H-chromen-4-yl)-1H-indole derivatives (I) on NO release

[0074] Inflammatory effects are associated with many inflammatory mediators, including cytokines, NO, and enzymes, which are released when macrophages produce different phenotypes in response to stimulation. NO is catalyzed by iNOS and is considered an important mediator in the inflammatory process. It is reported to affect the products of the cyclooxygenase metabolic pathway and produce two cyclooxygenase isoforms, COX-1 and COX-2. The inflammatory factor NO can be detected by Griess reagent. RAW 264.7 cell line was taken for determination, and 1×10 cells were seeded in each well of a 96-well plate. 5 cells, cultured in a DMEM complete medium with 10% fetal bovine serum and 1% penicillin and streptomycin, in a 37°C constant temperature incubator containing 5% CO2. 24 hours after inoculation of the cells, 10 μM compound (I) or positive drug (both dissolved in DMSO, DMSO final concentration of 0.5%) was added, 1 hour later, lipopolysaccharide (LPS) was added to make the final concentration of 1 μg / mL, 100 μL of supernatant was taken from each well in a 96-well plate after 24 hours of culture, 50 μL of Griess reagent A was added, and cultured in a 37°C constant temperature incubator for 10 minutes, and then 50 μL of Griess reagent B was added, and cultured in a 37°C constant temperature incubator for 10 minutes. The absorbance at a wavelength of 550 nm was then measured using an enzyme marker.

[0075] The results are as follows Figure 2, most of the compounds can inhibit the release of NO to varying degrees, that is, they have in vitro anti-inflammatory activity. The structure-activity relationship (SAR) obtained based on the preliminary results of this example shows that by comparing I-23, I-25 and I-29, it can be concluded that the anti-inflammatory effect is better when there is a methoxy substitution at the 6th or 7th position on the chromene ring; by comparing I-25 and I-27, it can be inferred that the effect is better when the para position on the benzene ring at the 3-position of the chromene is substituted with a chlorine atom. Since compounds I-25, I-26 and I-29 show a stronger inhibitory effect on the release of NO than the positive drug indomethacin, the IC values ​​of these three compounds were further determined by concentration gradient experiments. 50 Values ​​(Table 1). IC of I-25 50 The value was the lowest among the four compounds tested (IC 50 =4.82±0.34μM), and positive drug indomethacin (IC 50 =4.93±0.56 μM). Therefore, I-25 was determined to be an active compound for further in vivo anti-inflammatory activity assay.

[0076] Table 1 Inhibitory effects of some target compounds on NO

[0077]

[0078] *RAW264.7 cells were pretreated with different concentrations (20, 10, 5, 2.5 and 1.25 μM) of the compound for 1 h, followed by the addition of LPS (1 μg / mL) for 24 h; the NO concentration in the culture supernatant was determined using Griess reagent.

[0079] Example 4

[0080] Inhibitory effect of compound I-25 on carrageenan-induced plantar swelling in rats

[0081] The rat paw swelling model induced by carrageenan can be used to detect local acute inflammatory reactions mediated by PGE2 production and to screen effective anti-inflammatory drugs. Male Wistar rats (n=6, weight 180-200g) were gavaged with the target compound I-25 or the positive drug indomethacin (suspended in 0.5% CMC-Na) at a dose of 20 mg / kg. One hour later, 0.1 mL of sterile saline solution containing 1% carrageenan (Sigma, USA) was subcutaneously injected into the plantar of the right hind foot of the rat. The control group was subjected to the same experimental conditions, but only the vehicle was gavaged. The paw volume was measured using a volume meter (Ugo Basile, Italy) before and at 1, 3, and 5 hours after the injection of carrageenan. The results are shown in Table 2. 5 hours after injection, the inhibition rates of I-25 and the positive drug indomethacin on rat paw swelling were almost the same, 29.63% and 27.78%, respectively, indicating that I-25 has a certain inhibitory effect on acute inflammation in rats.

[0082] Table 2 Inhibitory effect of I-25 on carrageenan-induced rat paw swelling

[0083]

[0084] *Ctrl (vehicle; 0.5% CMC-Na), Indomethacin, and I-25suspendedin 0.5% CMC-Na.n=6.

[0085] Example 5

[0086] Inhibitory effect of compound I-25 on granuloma induced by cotton ball implantation in mice

[0087] Chronic inflammation has obvious granuloma characteristics and multinucleated giant cells. Granuloma induced by cotton ball implantation is a chronic inflammation model that can evaluate the inhibitory effect of compounds on tissue proliferation in the late stage of inflammation. Male C57Bl / 6 mice weighing 26-28g were randomly divided into groups of 6 mice per group. After anesthesia with sodium pentobarbital (30mg / kg, intraperitoneal injection), the back was prepared and disinfected under sterile conditions, and then two sterile cotton balls (10mg) were subcutaneously implanted at the shoulder blades on both sides of the back of the mouse through aseptic surgery. Starting from the day of surgery, mice were gavaged every 24h for 7 consecutive days to give the target compound I-25 (20mg / kg), positive drug indomethacin (20mg / kg) or vehicle (0.5% CMC-Na). After the mice were killed with CO2 on the 8th day of the experiment, the cotton balls with granulation hyperplasia tissue around them were carefully peeled off surgically, and then the cotton balls were dried to constant weight at 60°C. The results were recorded as the difference between the final cotton ball dry weight and the initial cotton ball weight (10 mg), and the inhibition rate was calculated. Figure 3As shown, I-25 at both test concentrations can significantly inhibit the hyperplasia of granulation tissue caused by cotton ball implantation under the skin, and is dose-dependent. In addition, there is no significant difference in the inhibition rate between the 10mg / kg I-25 group and the 20mg / kg indomethacin group; and at the same test concentration (20mg / kg), the granulation weight in the I-25 group (average granulation weight 20.4mg, inhibition rate 43.2%) is significantly lower than that of the positive drug indomethacin (average granulation weight 35.9mg, inhibition rate 32.0%). The results of this test prove that compound I-25 has good anti-inflammatory ability in vivo, and has a certain therapeutic effect on symptoms such as tissue hyperplasia in chronic inflammatory reactions.

[0088] Example 6

[0089] Inhibitory effect of compound I-25 on acetic acid-induced writhing in mice

[0090] The acetic acid-induced mouse writhing model can be used to evaluate the analgesic effect of compounds in animals. Male C57Bl / 6 mice weighing 26-28g were randomly divided into 4 groups, with 6 mice in each group. The target compound I-25 (10 or 20 mg / kg), the positive drug indomethacin (20 mg / kg) or the vehicle (0.5% CMC-Na) was administered by gavage, and 0.6% acetic acid (v / v; 0.1 mL / 10g body weight) was injected into the abdominal cavity 30 minutes later to induce the writhing reaction of the mice. The number of writhing movements (i.e., abdominal contraction, dorsiflexion, and extension) of the mouse body within 20 minutes after 5 minutes of the injection was counted. The results are expressed as the number of writhing movements within a 20-minute period. The test results are as follows: Figure 4 As shown, both I-25 treatment doses significantly reduced the number of writhings in mice caused by acetic acid injection, proving that I-25 has good analgesic activity in vivo and is dose-dependent. In addition, at the same dose (20 mg / kg), I-25 showed a more significant analgesic effect than the positive drug indomethacin.

[0091] Example 7

[0092] Determination of the anti-inflammatory and analgesic effects of compound I-25 in adjuvant-induced arthritis model in rats

[0093] Adjuvant-induced arthritis (AIA) is an animal model of inflammatory and reactive rheumatoid arthritis and is an industry standard model for predicting the clinical efficacy of new nonsteroidal anti-inflammatory drugs. In addition, since the changes in the pathological state of animals after adjuvant injection are similar to clinical rheumatoid arthritis, the AIA model is also considered to be the most suitable for comparison with human rheumatoid arthritis. Arthritis was induced by subcutaneous injection of 0.1 mL of sterile mineral oil containing 10 mg / mL heat-killed Mycobacterium tuberculosis in the right hind foot of each Lewis rat (male, 150-170 g). Rats injected with the same dose of saline in the same site served as blank control groups. After 7 days of immunization, the immunized rats were randomly divided into 4 groups, with 6 rats in each group. From the 8th day to the 28th day of immunization, rats were treated by daily gavage of I-25 (10 and 20 mg / kg) and indomethacin (20 mg / kg) suspended in 0.5% sodium carboxymethylcellulose. The blank control group and the model group were gavaged with an equal amount of 0.5% sodium carboxymethylcellulose every day. The body weight and volume of the left hind paw of the rats were measured every 2 days, and standardized clinical scores were performed on the three non-treated paws (the symptoms of each paw were scored from 0 to 4 from mild to severe, and the highest score for each rat was 12). On the 28th day of immunization, the rats were placed in a test cage with a wire mesh at the bottom for 30 minutes of acclimatization. Subsequently, the center of the left hind paw of the rats was mechanically stimulated using von Frey fibers (North Coast, USA) and the "up and down" method provided by the equipment manufacturer to measure the force that caused the rats to retract their paws or cry. The specific operation methods and data statistics were carried out according to the specific instructions given by the equipment manufacturer. The results are shown in Figure 2. Figure 5 As shown, compound I-25 significantly improved the weight loss of rats caused by adjuvant in a dose-dependent manner ( Figure 5 A) Swelling of paws ( Figure 5 B) and clinical symptoms of redness, swelling and deformation of the paws ( Figure 5 C). In addition, the 50% mechanical pain threshold (50% MWT) of the rats in the compound I-25 treatment group was significantly higher than that in the model group, showing good analgesic activity ( Figure 5 D), which also indicates that compound I-25 can relieve the tenderness symptoms of rheumatoid arthritis clinically. In addition, compound I-25 can also improve the splenomegaly caused by adjuvant injection, which means that it may have a certain immunomodulatory effect. Based on the above results, I-25 has positive significance for treating the symptoms and pain of patients with rheumatoid arthritis and improving their quality of life.

[0094] Example 8

[0095] Determination of acute gastric ulcer level induced by compound I-25 in rats

[0096] One of the controversial aspects of NSAIDs in clinical use is their serious side effects, among which the highest incidence is gastrointestinal side effects (2-4% of patients taking the drug experience serious complications each year), which also leads to the current NSAIDs not being able to fully meet medical needs. Therefore, improving the gastrointestinal safety of NSAIDs is of great significance for patients who are suitable for a wider range of long-term medication. Therefore, we studied the effect of oral administration of compound I-25 on the potential ulcerogenic effect of rats.

[0097] Male Wistar rats (180-200 g, n=5) were given vehicle (0.5% CMC-Na) or target compound I-25 (50 or 100 mg / kg) or indomethacin (50 mg / kg) by oral gavage. Six hours after administration, the rats were killed, and the stomach was surgically removed and cut open along the greater curvature. The ulcer injury index of the rats was calculated according to the following scoring scheme:

[0098] 1. Measure the diameter and length of the ulcer lesion with a vernier caliper;

[0099] 2. Ulcers are defined as grade I, ulcer areas with a diameter less than 1 mm; grade II, ulcer areas with a diameter of 1 to 3 mm; and grade III, ulcer areas with a diameter greater than 3 mm.

[0100] 3. The sum of the ulcer readings of the five test animals in each group was reported as the ulcer index (UI), calculated as follows: 1×number of grade I ulcers+2×number of grade II ulcers+3×number of grade III ulcers.

[0101] The results are shown in Table 3. At a dose of 50 mg / kg, indomethacin was administered orally to 5 rats to cause 32 gastric ulcer wounds and an ulcer index (UI) of 48, while I-25 did not cause acute ulcer symptoms at the same dose. Subsequently, rats were given a high concentration of 100 mg / kg of I-25 orally, which showed a slight ulcerogenic effect in these rats, causing a total of 12 grade I and grade II ulcer wounds, no grade III ulcers, and an ulcer index of 15, which was much lower than the ulcer damage caused by indomethacin at a concentration of 50 mg / kg.

[0102] Table 3 Comparison of acute gastric ulcers induced by I-25 and indomethacin in rats

[0103]

[0104] *Ctrl (vehicle; 0.5% CMC-Na), Indomethacin and I-25suspendedin 0.5% CMC-Na.n=5.

[0105] The above embodiments are only preferred embodiments for fully illustrating the present invention, and the protection scope thereof is not limited thereto. Equivalent substitutions or changes made by technicians in the technical field on the basis of the present invention are all within the protection scope of the present invention, and the protection scope of the present invention shall be subject to the claims.

Claims

1. A 3-(2-trifluoromethyl-3-aryl-4H-chromen-4-yl)-1H-indole derivative, characterized in that: It has the structure shown in the following general formula (I): in, R 1 Any one selected from a five-membered aromatic ring or a six-membered aromatic ring substituted with hydrogen, halogen, a C6 or lower hydrocarbon group, a C3 or lower fluoroalkyl group, or a C4 or lower alkoxy group; R 2 Any one or combination selected from hydrogen, halogen, C5 or less alkyl and alkoxy substituted at any position; R 3 Any one or a combination thereof selected from hydrogen substituted at any position, an alkyl group of less than C5, and an alkoxy group.

2. The 3-(2-trifluoromethyl-3-aryl-4H-chromen-4-yl)-1H-indole derivative according to claim 1, characterized in that R 1 Selected from -C6H5, -2-F-C6H4, -3-F-C6H4, -4-F-C6H4, -2-Cl-C6H4, -4-Cl-C6H4, -3-Br-C6H4, -4-Br-C6H4, -4-CF3-C6H4, -2-OCH3-C6H4, -4-OCH3-C6H4, -3-CH3-C6H4, -4-CH3-C6H4, -4-Ph-C6H4 or thienyl.

3. The 3-(2-trifluoromethyl-3-aryl-4H-chromen-4-yl)-1H-indole derivative according to claim 1, characterized in that R 2 Any one or combination of -H, -F, -Cl, -CH3, and -OCH3 is selected to substitute at any position.

4. The 3-(2-trifluoromethyl-3-aryl-4H-chromen-4-yl)-1H-indole derivative according to claim 1, characterized in that R 3 Any one or a combination of -H, -CH3, -OCH3 substituted at any position is selected.

5. An anti-inflammatory drug, characterized in that: The component comprises the 3-(2-trifluoromethyl-3-aryl-4H-chromen-4-yl)-1H-indole derivative according to any one of claims 1 to 4.

6. A method for preparing a 3-(2-trifluoromethyl-3-aryl-4H-chromen-4-yl)-1H-indole derivative, characterized in that: The synthetic route is: In formula (I)-(V), R 1 , R 2 , R 3 The definition is the same as that of claim 1.

7. The method for preparing a 3-(2-trifluoromethyl-3-aryl-4H-chromen-4-yl)-1H-indole derivative according to claim 6, characterized in that: The specific synthesis method is: Using a 2-aryl substituted carboxylic acid represented by formula (V) as a raw material, a ketone compound represented by formula (IV) is prepared by Friedel-Crafts acylation reaction; Using a ketone compound represented by formula (IV) as a raw material, an ester / ketone exchange reaction is performed to generate a (Z)-trifluoromethanesulfonic acid trifluoromethyl alkenyl ester compound represented by formula (III); The (Z)-trifluoromethanesulfonic acid trifluoromethyl alkenyl ester compound represented by formula (III) is used as a raw material, and R 2 The substituted salicylaldehyde undergoes a condensation cyclization reaction to produce a 2-trifluoromethyl-2-hydroxy-3-aryl-2H-chromene represented by formula (II); Then, 2-trifluoromethyl-2-hydroxy-3-aryl-2H-chromene represented by formula (II) is used as a raw material and R 3 The substituted indole undergoes a nucleophilic substitution reaction to produce a 3-(2-trifluoromethyl-3-aryl-4H-chromen-4-yl)-1H-indole derivative represented by formula (I).

8. Use of a 3-(2-trifluoromethyl-3-aryl-4H-chromene-4-yl)-1H-indole derivative, characterized in that: Used for preparing anti-inflammatory and analgesic drugs.

9. Use of the 3-(2-trifluoromethyl-3-aryl-4H-chromen-4-yl)-1H-indole derivative according to claim 8 for preparing a medicament for treating acute and chronic inflammation including rheumatoid arthritis.

Citation Information

Patent Citations

  • Heterocyclic itk inhibitors for treating inflammation and cancer

    CN107278202A

  • Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents

    CN1246856A

  • Quinoline-indole antimicrobial agents, uses and compositions related thereto

    US6103905A

  • Thiazolidine compounds, and methods of making and using same

    WO2009026346A1